A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP

Seike, Junichi; Sawada, Toru; Kawakita, Naoya; Yamamoto, Yota; Yuasa, Yasuhiro; Yamai, Hiromichi; Takachi, Hirokazu; Yoshida, Takahiro; Tangoku, Akira

doi:10.1155/2011/715623

Cited by 29 publications

(30 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…36 Rikkunshito, a traditional herbal medicine, is also known as a ghrelin potentiator 37 and has been shown to reduce cisplatin-induced anorexia in patients with gastrointestinal cancers in randomized controlled trials. 38,39 Anamorelin, a selective ghrelin receptor agonist, is a promising therapeutic agent for treating cancer cachexia and reducing cancer-associated anorexia or muscle wasting among cachectic patients with advanced NSCLC. 40,41 Although we did not consider interventions other than antiemetics, our results indicated that the successful management of CIA may have a stronger protective impact on nutritional status, body mass, and skeletal muscle than does CINV management.…”

Section: Discussionmentioning

confidence: 99%

Management of anorexia prevents skeletal muscle wasting during cisplatin‐based chemotherapy for thoracic malignancies

Miyawaki

Naito

Nakashima

et al. 2020

JCSM Clinical Reports

View full text Add to dashboard Cite

BackgroundCancer‐associated skeletal muscle loss often occurs in patients with advanced lung cancer who are receiving chemotherapy. This study aimed to elucidate the impact of chemotherapy‐induced nausea and vomiting (CINV) or anorexia on muscle wasting.MethodsIn this post‐hoc analysis of a phase II clinical trial of antiemetic agents, chemotherapy‐naïve Japanese patients with thoracic malignancies were prospectively recruited between May and October 2015. Total control of CINV was defined as the absence of nausea and vomiting without rescue therapy 0–120 h after each course of chemotherapy. Non‐anorexia was defined as having no anorexia or having an anorexia grade no higher than ‘1’ during the 3 month period following chemotherapy initiation. Skeletal muscle mass was measured by computed tomography, and lumbar skeletal muscle index (LSMI) was calculated.ResultsAmong 29 patients, CINV was totally controlled in 7 (24%) and grade 2 or 3 anorexia was observed in 10 (34%). The LSMI significantly decreased across the entire cohort (mean ± standard error of the mean: −3.1 ± 0.6 cm2/m2, P < 0.01); this reduction was similar among patients with and without total control of CINV (−4.1 ± 1.3 vs. −2.8 ± 0.7 cm2/m2, P = 0.38). Patients with anorexia experienced a larger decrease in LSMI than did those without anorexia during the study period (−5.4 ± 0.9 vs. −1.9 ± 0.7 cm2/m2, P < 0.01).ConclusionsSignificant skeletal muscle mass depletion was observed despite well‐controlled CINV. Continuous oral food intake may be required throughout the course of cisplatin‐based chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Management of anorexia prevents skeletal muscle wasting during cisplatin‐based chemotherapy for thoracic malignancies

Miyawaki

Naito

Nakashima

et al. 2020

JCSM Clinical Reports

View full text Add to dashboard Cite

show abstract

“…Furthermore, Seike et al . investigated the efficacy of Rikkunshito on CINV in patients with advanced esophageal cancer receiving chemotherapy with docetaxel and 5‐FU plus cisplatin . The nausea score of those on Rikkunshito supplementation was significantly lower than that in those without Rikkunshito supplementation.…”

Section: Discussionmentioning

confidence: 99%

Preventive effect of Rikkunshito, a traditional Japanese medicine, on chemotherapy‐induced nausea and vomiting with cisplatin: Case series

Kajiura

Hosokawa

Yoshita

et al. 2015

Traditional & Kampo Medicine

View full text Add to dashboard Cite

Aim: Supportive therapies are important to treat chemotherapy-induced nausea and vomiting (CINV). Rikkunshito, a Kampo medicine, has been reported to be effective against cisplatin-induced anorexia in rats. In the present study, we evaluated the preventive effect of Rikkunshito for CINV in patients receiving high-dose cisplatin chemotherapy. Methods: We selected patients who received chemotherapy including cisplatin (≥60 mg/m 2 ) for gastric or esophageal cancer between April 2010 and August 2012. We identified 20 patients treated without a reduction in the dose of anticancer medications during the second course and added 7.5 g/day Rikkunshito, which was orally administered, for 7 days. All patients were treated with 5-hydroxytryptamine-3 receptor antagonist, corticosteroid, and neurokinin-1 receptor antagonist for the prevention of CINV during the first and second courses. We evaluated complete response (CR; defined as no emesis and no rescue medication) and other toxicities according to the Common Terminology Criteria for Adverse Events version 4.0. Results: The median patient age was 63 years (range, 49-77 years). The chemotherapy regimens used were cisplatin plus 5-fluorouracil in 15 patients with esophageal cancer and cisplatin plus S-1 in five patients with gastric cancer. Rate of delayed CR was 75.0% during the first course (95% CI: 56.0-94.0%), which improved during the second course to 95.0% (95% CI: 85.4-100%, P = 0.077). There was no significant difference in other major toxicities between the first and second courses. Conclusion: Rikkunshito has the potential to alleviate CINV in patients receiving high-dose cisplatin chemotherapy. KEY WORDS: chemotherapy-induced nausea and vomiting, cisplatin, esophageal cancer, gastric cancer, RikkunshitoGinger (g) 0.5Figure 1 | Three-dimensional high-performance liquid chromatography profile of rikkunshito.

show abstract

“…Twenty-four patients aged from 52 to 81 years-old (21 males and 3 females, mean age, 64.7 !7.7 years), who received chemotherapy with weekly docetaxel, and low dose 5-FU and CDDP (DFP therapy) as the first regimen specified for esophageal cancer at the Tokushima University Hospital (13,14) from June, 2012 to July, 2015 were initially enrolled in the study. The patients with severe infection, onset of severe complication and allergy against drug were excluded from this study.…”

Section: Study Participantsmentioning

confidence: 99%

Impact of the use of Kampo medicine in patients with esophageal cancer during chemotherapy:a clinical trial for oral hygiene and oral condition

et al. 2018

Self Cite

View full text Add to dashboard Cite

Objective : The aim of this study was to investigate the impact of the use of two Kampo medicines on oral mucositis, tongue coating bacteria, and gingiva condition in patients with esophageal cancer undergoing chemotherapy. Methods : Twenty -three esophageal cancer patients who receive chemotherapy at Tokushima University Hospital, were included. The participants, who received professional oral healthcare, were randomly divided into three groups : 7 subjects received Daiokanzoto sherbets, 7 subjects received Hangeshashinto sherbets, and 9 subjects received nothing (control). The numbers of total bacteria and specific periodontopathogenic bacteria in tongue coating were determined in addition to clinical parameters. Results : No difference on the onset of oral mucositis was found among the three groups. However, tongue coating index, gingival index (GI), plaque index, the number of total bacteria, Fusobacterium nucleatum and Campylobacter rectus were decreased during chemotherapy. More specifically, GI as well as the number of F. nucleatum and C. rectus were decreased significantly in the Daiokanzoto group when compared to the control group (p!0.05). No such differences were observed for the group receiving Hangeshashinto. Conclusion : This clinical trial showed that Daiokanzoto might be effective in attenuating gingival inflammation and reducing the levels of periodontopathogenic bacteria in patients with esophageal cancer.

show abstract

A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP

Cited by 29 publications

References 28 publications

Management of anorexia prevents skeletal muscle wasting during cisplatin‐based chemotherapy for thoracic malignancies

Management of anorexia prevents skeletal muscle wasting during cisplatin‐based chemotherapy for thoracic malignancies

Preventive effect of Rikkunshito, a traditional Japanese medicine, on chemotherapy‐induced nausea and vomiting with cisplatin: Case series

Impact of the use of Kampo medicine in patients with esophageal cancer during chemotherapy:a clinical trial for oral hygiene and oral condition

Contact Info

Product

Resources

About